tisotumab vedotin-tftv (Tivdak from Seagen) is part of the numerous monoclonalantibodies produced by recombinant dna technology in mammalian Chinese hamster ovary (CHO) cells approved by the the fda in 2021.
Tivdak is indicated for the treatment of adult patients with recurrent or metastatic cervicalcancer with disease progression on or after chemotherapy.
Tisotumab is a human IgG1K antibody composed of two kappa light chains and two IgG1 heavy chains
Are you involved in R&D on monoclonal antibodies ?
Are you planning to screen different protein variants?
We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
A Historic Milestone: Magellan Biologics & Consulting Enters a New Era with ARCHIMED
Magellan Biologics and its sister company ExcellGene have entered a new strategic partnership with ARCHIMED, a global med-tech investment firm Press Release ARCHIMED acquires cell
25 September 2025
